JPRN-UMIN000001411
Completed
未知
Clinical pharmacology and pharmacogenetic study on the clinical response for tamoxifen - Clinical pharmacology and pharmacogenetics of tamoxifen
Saitama Medical University, Saitama International Medical Center0 sites100 target enrollmentOctober 3, 2008
ConditionsBreast cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Breast cancer
- Sponsor
- Saitama Medical University, Saitama International Medical Center
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Tamoxifen contraindication. Patients with (possibly) pregnant, with lactation. Patients possibly suffering from allergic reaction, severe liver or kidney dysfunction. 2\. Patients who are judged by doctors as inadequate to enroll this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Research of pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of 5-Fluorouracil in colorectal cancer patientsColorectal cancerJPRN-UMIN000004095Department of clinical pharmacokinetics, Graduate school of Pharmaceutical Science, Kyushu University30
Recruiting
Phase 2
A clinical trial to evaluate the effect of an Ayurvedic medicine, varyadi kashaya in patients with raised blood levels of uric acid.Health Condition 1: M109- Gout, unspecifiedCTRI/2023/03/050452INSTITUTE OF POST GRADUATE AYURVEDIC EDUCATION AND RESEARCH AT S.V.S.P.
Completed
Not Applicable
Pharmacokinetics and pharmacogenomics study with erlotinib in the treatment of advanced non-small cell lung cancer (NSCLC)on-small cell lung cancerJPRN-UMIN000006634Department of Respiratory Medicine / Keio Cancer Center, School of Medicine, Keio University40
Active, not recruiting
Not Applicable
Aspects Pharmacogénétiques et Pharmacocinétiques de la réponse à la CHimiothérapie d’induction par Docetaxel, Cisplatine et 5-Fluorouracile (TPF), des cancers OREUCTR2008-006874-14-FRCHU de Nîmes
Not yet recruiting
Phase 1
The Pharmacogenetic and Pathological Assessment of CYP2C19 Activity in Patients with Advanced CancerAdvanced cancerCancer -ACTRN12605000393651Cancer Trials New Zealand50